Aminolevulinic Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
methoxsalen
Melanizing agent, Synthetic psoralen, Furocoumarin · Melanizing agent
Melanizing agent, Synthetic psoralen, FurocoumarinMelanizing agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
3 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- Aminolevulinic AcidSevereDatabaseDDInter
- RasagilineSevereDatabaseDDInter
- TizanidineSevereDatabaseDDInter
Mechanism
Sensitizes skin to sunlight, which then induces erythema, inflammation, and pigmentation. On photoactivation, it stimulates melanocytes and induces their proliferation.
Indications
VitiligoAcceleration of tanning (maximum 2 weeks treatment)Lichen planusUrticaria pigmentosaAtopic dermatitisCutaneous T cell lymphoma
Dosing
- Adult
- Oral: 0.3–0.6 mg/kg (usually 20 mg) on alternate days, 2 hours before UVA exposure; Topical: 1% solution
Pharmacokinetics
Onset
Sensitization of skin is maximal at 1–2 hours
Duration
Sensitization lasts for 8 hours or more
Half-life
~1 hr
Side effects
Common
MottlingErythemaBurnsBlisteringPremature ageing of skinGastric discomfortNervousnessInsomnia
Drug interactions
Rasagiline
Severe
Database
Clinical effect not specified
Source: DDInter
Tizanidine
Severe
Database
Clinical effect not specified
Source: DDInter
9 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Melanizing agent, Synthetic psoralen, Furocoumarin drugs
Ask House about methoxsalen
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team